Shares of Definium Therapeutics (DFTX) jumped over 50% on Monday morning after the company announced positive topline results from its Phase 3 Emerge study of DT120 in major depressive disorder.
The stock is currently trading at $37.06, up $12.58 or 51.39%, on the Nasdaq. It opened at $38.74 after closing the previous session at $24.48. The stock has traded between $6.34 and $39.16 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.